NO20090606L - Aminofosforsyreester derivat og S1P reseptor modulator inneholdende den samme som aktiv ingresiens - Google Patents

Aminofosforsyreester derivat og S1P reseptor modulator inneholdende den samme som aktiv ingresiens

Info

Publication number
NO20090606L
NO20090606L NO20090606A NO20090606A NO20090606L NO 20090606 L NO20090606 L NO 20090606L NO 20090606 A NO20090606 A NO 20090606A NO 20090606 A NO20090606 A NO 20090606A NO 20090606 L NO20090606 L NO 20090606L
Authority
NO
Norway
Prior art keywords
active ingredient
acid ester
same
ester derivative
receptor modulator
Prior art date
Application number
NO20090606A
Other languages
English (en)
Inventor
Yasushi Kohno
Kiyoshi Fujii
Tatsuhiro Saito
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of NO20090606L publication Critical patent/NO20090606L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)

Abstract

Tilveiebringe aminofosfatderivat som har en utmerket sfingosin-1-fosfat (S1P) reseptormodulerende virkning. Som et resultat av fortsatt intensiv forskning for å tilveiebringe en meget sikker forbindelse som har en S1P reseptormodulerende virkning, er det oppdaget at et aminofosfatderivat representert ved den følgende generelle formel (1), har en sterk S1P reseptormodulerende virkning.
NO20090606A 2006-08-08 2009-02-10 Aminofosforsyreester derivat og S1P reseptor modulator inneholdende den samme som aktiv ingresiens NO20090606L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006215280 2006-08-08
PCT/JP2007/065397 WO2008018427A1 (fr) 2006-08-08 2007-08-07 Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif

Publications (1)

Publication Number Publication Date
NO20090606L true NO20090606L (no) 2009-03-03

Family

ID=39032957

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090606A NO20090606L (no) 2006-08-08 2009-02-10 Aminofosforsyreester derivat og S1P reseptor modulator inneholdende den samme som aktiv ingresiens

Country Status (27)

Country Link
US (1) US8232319B2 (no)
EP (1) EP2058317B1 (no)
JP (1) JP5188972B2 (no)
KR (1) KR101339976B1 (no)
CN (1) CN101501049B (no)
CA (1) CA2659598A1 (no)
CY (1) CY1114681T1 (no)
DK (1) DK2058317T3 (no)
ES (1) ES2438265T3 (no)
HK (1) HK1131154A1 (no)
HR (1) HRP20131172T1 (no)
IL (1) IL196275A (no)
MA (1) MA30663B1 (no)
ME (1) ME02095B (no)
MX (1) MX2009001456A (no)
MY (1) MY152176A (no)
NO (1) NO20090606L (no)
NZ (1) NZ574011A (no)
PL (1) PL2058317T3 (no)
PT (1) PT2058317E (no)
RS (1) RS53080B (no)
RU (1) RU2430925C2 (no)
SG (1) SG174028A1 (no)
SI (1) SI2058317T1 (no)
TN (1) TNSN08545A1 (no)
WO (1) WO2008018427A1 (no)
ZA (1) ZA200900206B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
WO2009142194A1 (ja) * 2008-05-19 2009-11-26 杏林製薬株式会社 光学活性アミノアルコール誘導体の製造方法
US20110152275A1 (en) * 2008-05-20 2011-06-23 Kazuhiko Kuriyama Agent for maintenance of induced remission
EP2326621B1 (en) 2008-07-23 2016-06-08 Arena Pharmaceuticals, Inc. SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
NZ591001A (en) 2008-08-27 2012-11-30 Arena Pharm Inc Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
AU2010269668B2 (en) * 2009-07-09 2013-12-19 Kyorin Pharmaceutical Co., Ltd. Diphenyl sulfide derivatives and medicines containing same as active ingredient
EP3378854B1 (en) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
SG183416A1 (en) 2010-03-03 2012-09-27 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
TWI519539B (zh) 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
US8513418B2 (en) * 2011-04-18 2013-08-20 Allergan, Inc. Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
CN102863345A (zh) * 2011-07-06 2013-01-09 中国医学科学院药物研究所 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途
WO2015194157A1 (ja) * 2014-06-16 2015-12-23 杏林製薬株式会社 ジフェニルスルフィド誘導体の製造方法及び製造中間体
KR102595163B1 (ko) 2015-01-06 2023-10-30 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 상태의 치료 방법
WO2016209809A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
PL3465886T3 (pl) 2016-06-07 2023-01-09 Tesla, Inc. Układ chłodzący silnik elektryczny
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
US10967702B2 (en) 2017-09-07 2021-04-06 Tesla, Inc. Optimal source electric vehicle heat pump with extreme temperature heating capability and efficient thermal preconditioning
CN112955431A (zh) 2018-09-06 2021-06-11 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
MX2021010217A (es) 2019-02-26 2021-09-21 Bayer Ag Derivados heterociclos biciclicos condensados como plaguicida.
JP2023548475A (ja) * 2020-11-09 2023-11-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関係する病態を治療する方法
US11932078B2 (en) 2021-03-31 2024-03-19 Tesla, Inc. Electric vehicle heat pump using enhanced valve unit

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
US5948820A (en) 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
US5447922A (en) 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
CN1137086C (zh) 1997-04-04 2004-02-04 三菱制药株式会社 2-氨基丙烷-1,3-二醇化合物、其作为医药的用途及其合成中间体
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
ATE358484T1 (de) 1998-07-02 2007-04-15 Kyowa Hakko Kogyo Kk Antidiabetische medikamente
AU767241B2 (en) 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
US20020143034A1 (en) 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
AU2001264313A1 (en) 2000-06-20 2002-01-02 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
JP2002053575A (ja) 2000-08-09 2002-02-19 Sankyo Co Ltd アミノアルコ−ル類
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
ATE446303T1 (de) 2001-01-30 2009-11-15 Univ Virginia Agonisten und antagonisten von sphingosin-1- phosphatrezeptoren
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
EP1368015B1 (en) 2001-02-22 2006-08-09 Novartis AG Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
DE60208355T2 (de) 2001-03-26 2006-07-27 Novartis Ag 2-amino-propanol derivate
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
DE60230262D1 (de) 2001-05-10 2009-01-22 Ono Pharmaceutical Co Carbonsäurederivate und diese als wirkstoff enthaltende arzneimittel
JP2004534772A (ja) 2001-05-24 2004-11-18 藤沢薬品工業株式会社 アミノアルコール誘導体
US20040235794A1 (en) 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
DK1431284T3 (da) 2001-09-27 2008-02-18 Kyorin Seiyaku Kk Diarylsulfidderivat, additionssalt deraf samt immunundertrykkende middel
JP4035759B2 (ja) 2001-11-06 2008-01-23 独立行政法人産業技術総合研究所 アミノアルコールリン酸化合物、製造方法、及びその利用方法
JP2005112721A (ja) 2001-11-06 2005-04-28 Maruha Corp 含窒素化合物、製造法、及びその利用方法
AU2002354476A1 (en) 2001-12-14 2003-06-30 Japan Tobacco Inc. Pyrazolopyridine derivatives and medicinal use thereof
JP2003267936A (ja) 2002-01-11 2003-09-25 Sankyo Co Ltd ベンゼン環化合物
BR0306811A (pt) 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
JP4771511B2 (ja) 2003-07-08 2011-09-14 第一三共株式会社 アミノアルコ−ル誘導体又はホスホン酸誘導体を含有する医薬組成物
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
CA2472680A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
CA2472715A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
WO2003074008A2 (en) 2002-03-01 2003-09-12 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
AU2003217764A1 (en) 2002-03-01 2003-09-16 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
EP1549640A4 (en) 2002-06-17 2008-08-06 Merck & Co Inc 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS
EP2508204B1 (en) 2002-06-26 2014-09-24 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
AU2003259296A1 (en) 2002-07-30 2004-02-16 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
AU2003273865A1 (en) 2002-09-13 2004-04-30 Novartis Ag Amino-propanol derivatives
JP4571497B2 (ja) 2002-09-19 2010-10-27 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
PL408347A1 (pl) 2002-09-24 2014-08-18 Novartis Ag Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P
EP1553075B1 (en) 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
JP4140698B2 (ja) 2002-10-18 2008-08-27 第一三共株式会社 リン酸又はホスホン酸誘導体
ATE496024T1 (de) 2002-12-20 2011-02-15 Merck Sharp & Dohme 1-(amino)indane als edg-rezeptoragonisten
CA2515638A1 (en) 2003-02-11 2004-08-26 Shifeng Pan Novel bicyclic compounds and compositions
ES2360394T3 (es) 2003-02-18 2011-06-03 Kyorin Pharmaceutical Co., Ltd. Derivados de ácido aminofosfónico, sales de adición de los mismos y moduladores del receptor s1p.
JP2004307442A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ヘテロ環誘導体とその付加塩及び免疫抑制剤
JP2004307441A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ベンゼン誘導体とその付加塩及び免疫抑制剤
JP2004307440A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩
JP2004307439A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd アミノジオール誘導体とその付加塩及び免疫抑制剤
JP4603531B2 (ja) 2003-04-30 2010-12-22 ノバルティス アーゲー スフィンゴシン−１−ホスフェートレセプターモジュレーターとしての、アミノプロパノール誘導体
AU2004234067B2 (en) 2003-04-30 2008-02-28 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
CN1788008A (zh) 2003-05-15 2006-06-14 麦克公司 作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑
MXPA05012460A (es) 2003-05-19 2006-05-25 Irm Llc Compuestos y composiciones inmunosupresoras.
CN1816544B (zh) 2003-05-19 2011-06-08 Irm有限责任公司 免疫抑制剂化合物和组合物
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
JP2005047899A (ja) 2003-07-11 2005-02-24 Sankyo Co Ltd アミノアルコール化合物
TW200505416A (en) 2003-08-12 2005-02-16 Mitsubishi Pharma Corp Bi-aryl compound having immunosuppressive activity
WO2005014603A1 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Phosphinane compounds with immunomodulating activity
PL1660449T3 (pl) 2003-08-28 2010-05-31 Novartis Ag Pochodne aminopropanolu
CN101407471A (zh) 2003-08-29 2009-04-15 小野药品工业株式会社 能够结合s1p受体的化合物及其药物用途
CA2539438A1 (en) 2003-10-01 2005-04-14 Merck And Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
GB0324210D0 (en) 2003-10-15 2003-11-19 Novartis Ag Organic compounds
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
JPWO2005044780A1 (ja) 2003-11-10 2007-05-17 杏林製薬株式会社 アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
EP1697333A4 (en) 2003-12-17 2009-07-08 Merck & Co Inc 3,4-DISUSBSTITUTED PROPANOIC CARBOXYLATES AS S1P RECEPTOR AGONISTS (EDG)
TW200526548A (en) 2003-12-25 2005-08-16 Sankyo Co Ether derivatives
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
JP4740884B2 (ja) 2004-02-24 2011-08-03 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制性化合物および組成物
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
WO2005079788A1 (ja) 2004-02-24 2005-09-01 Sankyo Company, Limited アミノアルコール化合物
JP2005247691A (ja) 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
GB0405289D0 (en) 2004-03-09 2004-04-21 Novartis Ag Organic compounds
GB0411929D0 (en) 2004-05-27 2004-06-30 Novartis Ag Organic compounds
US8039674B2 (en) 2004-06-23 2011-10-18 Ono Pharmaceutical Co., Ltd. Compound having S1P receptor binding potency and use thereof
US7781617B2 (en) 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
TW200611687A (en) 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
WO2006020951A1 (en) 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
CA2583846C (en) 2004-10-12 2013-10-01 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrates thereof, and intermediates in the production thereof
JPWO2006041015A1 (ja) 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
MX2007006706A (es) 2004-12-06 2007-10-18 Univ Virginia Analogos de esfingosina 1-fosfato amida de arilo.
TW200702326A (en) 2005-05-31 2007-01-16 Mitsubishi Pharma Corp 2-aminobutanol compound and its pharmaceutical use
TWI418350B (zh) 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
EP2295049B1 (en) 2005-09-09 2014-11-26 Novartis AG Treatment of autoimmune diseases
EP1932522B1 (en) 2005-10-07 2012-05-23 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for liver disease containing 2-amino-1,3-propanediol derivative as active ingredient
WO2007043568A1 (ja) 2005-10-12 2007-04-19 Toa Eiyo Ltd. Ｓ１ｐ３受容体拮抗剤
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
US8114902B2 (en) 2006-04-28 2012-02-14 Mitsubishi Tanabe Pharma Corporation 2-aminobutanol compound and use thereof for medical purposes
WO2008014338A2 (en) 2006-07-25 2008-01-31 Alcon Research, Ltd. Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders
US7877152B2 (en) 2006-07-31 2011-01-25 JusJas LLC Bipolar stimulation/recording device with widely spaced electrodes

Also Published As

Publication number Publication date
HK1131154A1 (en) 2010-01-15
HRP20131172T1 (hr) 2014-01-17
RU2430925C2 (ru) 2011-10-10
MY152176A (en) 2014-08-15
NZ574011A (en) 2011-10-28
US20090325907A1 (en) 2009-12-31
PT2058317E (pt) 2013-12-11
SG174028A1 (en) 2011-09-29
CY1114681T1 (el) 2016-10-05
MA30663B1 (fr) 2009-08-03
CN101501049B (zh) 2013-04-24
CA2659598A1 (en) 2008-02-14
AU2007282536A1 (en) 2008-02-14
EP2058317A4 (en) 2011-06-29
MX2009001456A (es) 2009-02-19
EP2058317B1 (en) 2013-10-16
ME02095B (en) 2014-06-30
IL196275A (en) 2013-10-31
RU2009106934A (ru) 2010-09-20
JPWO2008018427A1 (ja) 2009-12-24
JP5188972B2 (ja) 2013-04-24
DK2058317T3 (da) 2014-01-06
PL2058317T3 (pl) 2014-03-31
WO2008018427A1 (fr) 2008-02-14
ZA200900206B (en) 2009-12-30
IL196275A0 (en) 2009-09-22
US8232319B2 (en) 2012-07-31
ES2438265T3 (es) 2014-01-16
KR20090046929A (ko) 2009-05-11
TNSN08545A1 (en) 2010-04-14
RS53080B (en) 2014-06-30
SI2058317T1 (sl) 2014-01-31
EP2058317A1 (en) 2009-05-13
KR101339976B1 (ko) 2013-12-10
CN101501049A (zh) 2009-08-05

Similar Documents

Publication Publication Date Title
NO20090606L (no) Aminofosforsyreester derivat og S1P reseptor modulator inneholdende den samme som aktiv ingresiens
BR112013006531A2 (pt) composições fungicidas
MY159358A (en) Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
EA201070588A1 (ru) Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20091620L (no) Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
WO2009155121A3 (en) Inhibitors of pi3 kinase
MX2009005691A (es) Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i.
MA31080B1 (fr) Dérivés cyclisés en tant qu'inhibiteurs d'eg-5.
NO20092587L (no) LXR og FXR modulatorer
NZ600210A (en) Substituted 4-aminocyclohexane derivatives
CO6351685A2 (es) Metodo para controlar vegetacion mimosoideae no deseada
BR112012028857A2 (pt) formulações farmacêuticas que compreendem derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenzeno como inibidores de sglt
NO20061818L (no) Fremgangsmate for a inhibere remnant lipoproteinproduksjon
UA95481C2 (ru) Производные тетразола, фунгицидная композиция на их основе, применение их для радикальной или предупредительной борьбы с фитопатогенными грибами растений или злаковых культур и способ борьбы с фитопатогенными грибами
MX2009010302A (es) Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
UA94468C2 (ru) Производные тетразола, фунгицидная композиция на их основе, применение их для радикальной или предупредительной борьбы с фитопатогенными грибами растений или злаковых культур и способ борьбы с фитопатогенными грибами
WO2008119685A3 (en) Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators
BR0212435A (pt) Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase
NO20092528L (no) Krystallinske kaliumsalter av lipoksin A4-analoger

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application